Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Divergence in poxvirus-encoded E3-like proteins can dictate poxvirus activation of cellular necroptosis.

Journal of virology·2026
Same author

Poxvirus attack of antiviral defense pathways unleashes an effector-triggered NF-κB response.

Science (New York, N.Y.)·2026
Same author

Virus-derived serpin reduces immuno-coagulopathic damage in murine colitis by targeting the urokinase-type plasminogen activator receptor (uPAR) and complement.

Scientific reports·2025
Same author

Effect of Exportin 1/XPO1 Nuclear Export Pathway Inhibition on Coronavirus Replication.

Viruses·2025
Same author

Adipose-Derived Stem Cells as Carrier of Pro-Apoptotic Oncolytic Myxoma Virus: To Cross the Blood-Brain Barrier and Treat Murine Glioma.

International journal of molecular sciences·2024
Same author

Urokinase-Type Plasminogen Activator Receptor (uPAR) in Inflammation and Disease: A Unique Inflammatory Pathway Activator.

Biomedicines·2024

Related Experiment Video

Updated: Jan 27, 2026

Ex Vivo Infection of Live Tissue with Oncolytic Viruses
12:08

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Published on: June 25, 2011

13.3K

Poxvirus oncolytic virotherapy.

Lino E Torres-Domínguez1, Grant McFadden1

  • 1a Biodesign Center for Immunotherapy, Vaccines and Virotherapy , Arizona State University , Tempe , AZ , USA.

Expert Opinion on Biological Therapy
|March 29, 2019
PubMed
Summary
This summary is machine-generated.

Oncolytic virotherapy uses poxviruses to treat cancer by destroying tumor cells and stimulating immunity. Future research aims to improve viral delivery and overcome immune evasion for better cancer treatment outcomes.

Keywords:
Myxoma virusVaccinia virusoncolyticoncolytic virusvirotherapy

More Related Videos

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

9.9K
Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

9.5K

Related Experiment Videos

Last Updated: Jan 27, 2026

Ex Vivo Infection of Live Tissue with Oncolytic Viruses
12:08

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Published on: June 25, 2011

13.3K
Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

9.9K
Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

9.5K

Area of Science:

  • Oncology
  • Virology
  • Immunotherapy

Background:

  • Biological therapies offer new hope for incurable cancers.
  • Oncolytic virotherapy is a promising cancer treatment strategy.
  • Oncolytic viruses induce tumor cell death and anti-tumor immunity.

Purpose of the Study:

  • To review advances in poxvirus oncolytic virotherapy over the past five years.
  • To highlight the potential of oncolytic poxviruses (Vaccinia and Myxoma) in cancer treatment.
  • To discuss challenges and future directions in the field.

Main Methods:

  • Review of pre-clinical tumor models and clinical trials involving oncolytic poxviruses.
  • Summary of recent research on poxvirus-based oncolytic virotherapy.
  • Analysis of strategies to enhance viral delivery and overcome immune evasion.

Main Results:

  • Poxviruses show encouraging results in pre-clinical and clinical settings for various cancers.
  • Significant progress has been made in poxvirus oncolytic virotherapy.
  • Key challenges include optimizing viral delivery and tumor immune-evasion.

Conclusions:

  • Oncolytic poxvirus virotherapy is a developing cancer treatment modality.
  • Enhancing viral delivery and overcoming immune evasion are critical for success.
  • Combination with standard treatments, especially immunotherapies, holds great promise.